Objectives Pathologic staging tries to maintain symmetry with clinical staging, allowing a direct comparison of both. However, in contrast to clinical substaging of T2 prostate cancers, is controversial whether pathologic T2 substaging conveys prognostic information. The aim of our study is to analyze the clinicopathologic findings and the prognostic information comparing the clinical with the pathological T2 substaging of patients submitted to radical prostatectomy. Materials and methods Using the 2009 TNM staging system, 169 patients with clinical stage T2a were compared with patients with stage T2b/T2c, and 142 patients with pathological stage T2a were compared with patients with stage T2c. All surgical specimens were step-sectioned. Using a semiquantitative pointcount method for tumor extent evaluation, all insignificant tumors were excluded from analysis. Clinicopathological characteristics were compared between the groups. Biochemical recurrence data were compared using log-rank analysis, and significant predictors of time to biochemical recurrence were determined using univariate and multivariate Cox proportional hazards model. Results There was significant difference in biochemical recurrence rates between men with clinical T2a versus T2b/T2c tumors but no difference between men with pathological T2a versus T2c tumors. No patient in pathologic stage T2b was found. On multivariate analysis, clinical stage T2b/T2c was independent predictor of time to biochemical recurrence following surgery but not pathological stage T2c. Conclusions There is lack of symmetry between clinical and pathological T2 substaging as predictors of time to biochemical recurrence following surgery. The findings support a reevaluation of the TNM pathologic T2 stage, which should not be substratified.
Introduction
The clinical staging of prostate cancer is reflected by the detection methods employed. Substaging of clinical stage T2 prostate carcinoma is based on the extent of the abnormality palpated during a digital rectal examination. In the 2009 TNM system for prostate cancer, the clinical and pathological substaging of T2 cancers are classified into 3 groups: T2a (tumor involves onehalf of one lobe or less), T2b (tumor involves more than one-half of one lobe, but not both lobes), and T2c (tumor involves both lobes) [1] .
Pathologic staging tries to maintain symmetry with clinical staging, allowing a direct comparison of both. However, in contrast to clinical substaging of T2 prostate cancers, is controversial whether pathologic T2 substaging conveys prognostic information [2] [3] [4] [5] [6] . During a consensus conference sponsored by the International Society of Urological Pathology (ISUP) on handling and staging of radical prostatectomy specimens held in Boston during the 98th meeting of the United States and Canadian Academy of Pathology (USCAP), 65.5% of the attendants answered that the current pT2 substaging system should not be used [7] .
The aim of our study is to analyze the clinicopathologic findings and the prognostic information comparing the substaging of clinical stage T2 (cT2) versus the substaging of pathologic stage T2 (pT2) of Latin American patients submitted to radical prostatectomy.
Materials and methods
From 1997 to 2009, 360 consecutive patients underwent digital rectal examination (DRE) and radical retropubic prostatectomy by one surgeon (UF). This retrospective study was based on 169 patients with clinical stage T2N0 and 142 patients with pathological stage T2N0 from a prospectively maintained database. Clinical and pathological T2 substaging was defined according to the 2009 TNM classification into 3 groups: T2a (tumor involves one-half of one lobe or less), T2b (tumor involves more than one-half of one lobe, but not both lobes), and T2c (tumor involves both lobes).The clinicopathological variables studied included age at surgery, preoperative prostate-specific antigen (PSA) level, biopsy Gleason score, radical prostatectomy (RP) Gleason score, surgical margin status, and biochemical recurrence (BCR) following surgery.
After RP, serum PSA was drawn every 3 months during the 1 year, every 6 months during the 2 year, and annually thereafter. No patient of this series had radiotherapy or androgen manipulation before or after surgery. Total serum PSA was measured utilizing previous validated Immulite Ò PSA kit. BCR following surgery was considered as PSA [0.2 ng/mL according to recommendation of the American Urological Association [8] . Patients without evidence of BCR were censored at last follow-up. The present study was approved by the Institutional Committee of Ethics of our Institution.
A mean of 32 paraffin blocks was processed from surface inked step-sectioned surgical specimens, and 6-lm sections from each block were stained with hematoxylin and eosin. Each transversal section of the prostate was subdivided into 2 anterolateral and 2 posterolateral quadrants. The histopathological analysis was done by a senior Uropathologist (AB). Histological tumor grading was performed according to the ISUP modified Gleason grading system [9] . A positive surgical margin was defined as cancer cells in contact with the inked specimen surface. Pathological T2 substaging was based on a semiquantitative point-count method for evaluation of tumor extent [10, 11] . Briefly, drawn on a sheet of paper, each quadrant of the transversal sections contained 8 equidistant points. During the microscopic examination of the slides, the tumor area was drawn on the correspondent quadrant seen on the paper. At the end of the examination, the amount of positive points represented an estimate of the tumor extent. According to the method used, pT2a corresponds to tumors with less than half positive points of one lobe, pT2b to tumors with more than half positive points of one lobe, but not both lobes, and pT2c to tumors involving both lobes. We excluded from the study insignificant cancers defined as having volume \0.5 cc, which corresponds approximately to \10 positive points with the point-count method used, and no Gleason grade 4 or 5 component, primary, secondary, or tertiary. Therefore, either left and/or right lobe(s) contained significant tumors with [10 positive points.
Statistical analysis
The data were analyzed using the Fisher's exact test for comparison of proportions, the Mann-Whitney test for comparison of means, the Kaplan-Meier product-limit analysis for the time to biochemical recurrence (TBCR) using the log-rank test for comparison between the groups, and the univariate and multivariate Cox stepwise logistic regression model to identify significant predictors of TBCR. The P-values were two-sided at the significance level of \0.05. All statistical analyses were performed using the commercial available PASW Statistics (SPSS) 18.0.
Results

Clinical stage
From the total of 169 patients studied, 118/169 (69.8%) patients were clinical stage T2a, 41/169 (24.3%) patients were stage T2b, and 10/169 (5.9%) patients were stage T2c. Due to the small number of patients in clinical stage T2c, only two groups were considered for the purpose of analysis: cT2a and cT2b/cT2c. Clinicopathologic characteristics are summarized in Table 1 . There were no significant differences between the groups in age at surgery, preoperative PSA, biopsy Gleason score, RP Gleason score, or surgical margin status. Figure 1 shows the TBCR following surgery comparing the two groups. The mean, median, and range of follow-up were 35, 23, and 1-121 months. From a total of 155 patients with PSA determination, 55 (35.5%) patients (uncensored) had BCR. At 5 years, 65% of patients with clinical stage T2a were free of progression versus 44% of patients with clinical stage T2b/T2c. Log-rank analysis revealed a significant difference in PSA outcome between men with cT2a and cT2b/cT2c tumors (P = 0.01). Table 2 shows the predictors of TBCR on univariate and multivariate analyses. On univariate analysis, clinical stage T2b/T2c, preoperative PSA, biopsy Gleason score, RP Gleason score, and positive surgical margins were significant predictors of TBCR. Including all these variables on multivariate analysis, only clinical stage T2b/T2c, biopsy Gleason score, and positive surgical margins were significant predictors of TBCR. Table 3 . There were no significant differences between the groups in age at surgery, preoperative PSA, biopsy Gleason score, or surgical margin status. There was marginally (insignificant) difference in RP Gleason score. Figure 2 shows the TBCR following surgery comparing the two groups. The mean, median, and range of follow-up were 31, 25, and 1-114 months. From a total of 122 patients with PSA determination, 31 (25.4%) patients (uncensored) had BCR. At 5 years, 61% of patients with pathological stage T2a were free of progression versus 71% of patients with pathological stage T2c. Log-rank analysis revealed no significant difference in PSA outcome between men with pT2a and pT2c tumors (P = 0.68). Table 4 shows the predictors of TBCR on univariate and multivariate analyses. On univariate and multivariate analyses, only preoperative PSA and positive surgical margins were significant predictors of TBCR.
Discussion
The objective of staging is as follows: (1) to group malignancies with a similar prognosis and therapeutical approach; (2) to perform clinical trials or research studies on homogeneous patient populations; and (3) to enhance the comparability of clinicopathologic data from hospitals and research groups across the world [12] . In general, pathologic staging (or substaging) tries to maintain symmetry with clinical staging (or substaging), allowing a direct comparison of both. The clinical staging of prostate cancer is a reflection of the detection methods employed, and the substaging of clinical stage T2 prostate cancers is largely based on the extent of the abnormality palpated during a digital rectal examination or shown during transrectal ultrasonography in each half of the prostate. The 1997 TNM staging system classified T2 prostate cancers into 2 groups: T2a (unilateral tumor) and T2b (bilateral tumor) [13] . In 2002 and in 2009, the TNM staging system returned to the 1992 staging system classifying prostate cancers into 3 groups: T2a (unilateral tumor, involving less than half lobe), T2b (unilateral tumor, involving more than half lobe), and T2c (bilateral tumor) [1, 14] . The clinical 1992, 2002, and 2009 TNM T2 substaging into 3 categories conveys prognostic information and appears to be superior to the 1997 TNM T2 substaging into 2 categories in predicting the outcome [15] [16] [17] [18] .
On the other hand, several studies have shown that pathologic T2 substaging does not convey prognostic information [2] [3] [4] [5] [6] . This paradox may be apparently explained in part by the fact that clinical criteria used in assessing stage indirectly estimate the chance of understaging, and in this way, they seem to stratify the heterogeneous group of clinical stage T2 patients [12] . Smith and Catalona [19] found that the reproducibility of DRE for detecting prostate cancer is only fair among Urologists. Probably, most palpable cT2b tumors are already pT2c or T3 disease, explaining why clinical staging has a better correlation with prognosis. Obek et al. [20] reviewed 89 patients with clinically palpable tumors (cT2) to assess whether the clinicians characterization of the disease as unilateral or bilateral by DRE correlated with the final pathology specimen. In 85 patients, a unilateral lesion was suspicious in DRE. The final pathological review revealed cancer on the suspicious side in 82 cases (96%) with tumor confined to the same lobe in only 23 (27%), bilateral disease in 59 (69%) and tumor confined to the contralateral lobe in 3 (4%). On the clinically benign side on DRE, there was a 36 and 31% incidence of extraprostatic tumor extension and positive surgical margins, respectively.
During a consensus conference sponsored by the International Society of Urological Pathology (ISUP) on handling and staging of radical prostatectomy specimens held in Boston during the 98th meeting of the United States and Canadian Academy of Pathology (USCAP), 65.5% of the attendants answered that the current pT2 substaging system should not be used [7] . Answering to another question, 63.4% favored to be reduced to two categories based on studies, showing that pathological T2b tumor does not exist [5, 21, 22] .
In our study, clinical staging showed significant prognostic value. At 5 years, 65% of patients with clinical stage T2a were free of progression versus 44% of patients with clinical stage T2b/T2c. Log-rank analysis revealed a significant difference in PSA outcome (P = 0.01). On univariate and multivariate analyses, clinical stage T2b/T2c was a significant predictor of TBCR. On the other hand, at 5 years, 61% [2] from Germany, based on the 1992 TNM staging classification which stratified T2 stage into 3 groups (T2a, T2b, and T2c), analyzed the biochemical progression-free 5-year survival rates for pathological stage pT2. There was no significant difference in the pT2 subgroups: 83% (pT2a), 81% (pT2b), and 62%(pT2c). The authors concluded that there was an urgent need to develop a pathological equivalent to the TNM clinical staging system.
Freedland et al. [3] from Johns Hopkins Institutions, based on the 1997 TNM staging classification which stratified T2 stage into 2 groups (T2a, and T2b), analyzed whether the comparison between the pathologic groups provided prognostic significance. The authors evaluated biochemical outcomes between men with pT2aN0 and pT2bN0 disease. There were no significant differences between men with pT2a and pT2b tumors at the time of surgery in terms of clinicopathologic characteristics (biopsy and pathologic Gleason score, serum PSA level, clinical stage, and age). Log-rank analysis revealed no significant differences in TBCR between men with pT2a and pT2b tumors. Multivariate analysis showed that the significant predictors of PSA recurrence included serum PSA level, biopsy and pathologic Gleason score, and clinical stage. The authors concluded that consideration should be given to modifying the TNM staging system to eliminate substratification of pT2 tumors.
Chun et al. [4] examined the prognostic value of the 1997 or 1992/2002 TNM pT2 substages in prediction of biochemical recurrence after RP in European patients. In univariate analysis, neither the 1997 nor the 1992/2002 pT2 substages was predictive of recurrence. In multivariate analysis, the lack of significance persisted. The authors concluded that pT2 substages offer no incremental value relative to pretreatment total PSA, surgical margin status, and pathologic Gleason scores. Therefore, it might be postulated that it is sufficient to confirm organ confinement according to Partin's pathologic staging.
Van Oort et al. [5] from Netherlands, based on the 2002 TNM pT2 substages, studied the biochemical recurrence after radical prostatectomy considering the pathological substage. Patients with unilateral involvement had a 5-year risk for recurrence of 13%, while those with bilateral involvement (pT2c) had a risk of 23% (log-rank, P = 0.06). Patients with pT2c disease were more likely to have a larger tumor volume and positive surgical margins than those with pT2a tumors. There was no significant difference between the groups for preoperative PSA levels as well as for radical prostatectomy pathologic Gleason score. In the multivariate analysis, positive surgical margins appeared to increase the risk of recurrence with pT2c vs pT2a only a marginal (insignificant) effect. The authors conclude that the limited differences in recurrence and in pathological features of unilateral vs bilateral pT2 prostate cancer justify modifying the TNM staging system to one with no subclassification of pT2 disease or at most as only one subdivision into unilateral (T2a) and bilateral (T2b) disease, combining the T2b and T2c substages.
Hong et al. [6] from Korea assessed various clinicopathological features along biochemical recurrence-free survival from patients submitted to radical prostatectomy. Using the 1997 TNM pT2 substaging, they found no significant difference regarding biochemical recurrence in either uni-or multivariate analyses. Only preoperative serum PSA level and pathological Gleason score along positive surgical margin were significant predictors of biochemical recurrence on multivariate analysis. The authors conclude that two-or three-tiered subclassification of pT2 organ-confined prostate cancer via methods used in the 1997 or 2002 TNM staging system may not be appropriate, and efforts should be made to upgrade the current TNM staging system for prostate cancer.
The absence of pT2b cases in our series confirms other studies in the literature. Eichelberger et al. [21] studied 276 prostate specimens from patients submitted to radical prostatectomy. Using the 2002 TNM staging criteria, 54 of the tumor specimens (15%) were classified as pT2a, and 222 (60%) were pT2c. No pathologic T2b tumor specimens were identified. Quintal et al. [22] studied 166 prostate specimens from patients submitted to radical prostatectomy. According to the 2002 TNM staging criteria, 28/166 (16.9%) of the tumor specimens were pT2a, and 138/166 (83.1%) were pT2c. Using a semiquantitative point-count method for tumor extent evaluation, no specimen with unilateral involvement presented more than half points; therefore, no specimen pT2b was found. van Oort et al. [5] examined 360 prostate specimens from patients submitted to radical prostatectomy. According to the 2002 TNM staging system, 79 (22%) of the radical prostatectomy specimens were staged as pT2a, and 281 (78%) were pT2c. No pT2b specimens were identified.
A limitation of the current study is the small sample size and the relative short time of follow-up. However, the small sample reflects the exclusion criteria in our series. The multifocality seen in 83-87% of prostate cancers [23, 24] is one major cause for the absence of symmetry between clinical and pathological T2 substaging. Prostate cancer may be extensive on one lobe (index tumor) and only insignificant on the other side. Should this case be considered pT2c? In this particular example, what should be a minimum extent for a case to be considered bilateral? During the consensus conference sponsored by the International Society of Urological Pathology held in Boston during the 98th meeting of the United States and Canadian Academy of Pathology, there was no consensus regarding definition of index tumor, and the minimum size for a second tumor to be considered for the whole case to be classified as pT2c [7] . It was proposed during the consensus conference that for a tumor to be classified as pT2c, the contralateral tumor should be at least 1 cm in diameter (approximately equal to 0.5 cc). Our study is the only one to consider tumor extent as selection criteria excluding insignificant cancers evaluated by the point-count semiquantitative method used. Considering only significant tumors, our pathologic stage T2c more probably represents a true bilateral tumor. Yet, true bilateral tumors assessed pathologically do not confer prognostic information compared with those clinically judged.
Conclusions
There is significant difference in BCR rates between men with clinical T2a versus T2b/T2c tumors but no difference between men with pathological T2a versus T2c tumors. On multivariate analysis, clinical stage T2b/T2c is independent predictor of TBCR following surgery but the same does not happen with pathological stage T2c. No patient in pathologic stage T2b was found. Our findings with Latin American patients are similar to other studies from the United States, Europe, and Asia. There is lack of symmetry between clinical and pathological T2 staging as predictors of TBCR following RP. Possible causes for the discrepancy include multifocality of prostate cancer, no definition for index tumor among pathologists, nonexistence of pT2b stage, and the fact that clinical criteria used in assessing stage indirectly estimate the chance of understaging. The findings support a reevaluation of the TNM pathologic T2 stage, which should not be substratified.
